drugset
drugset / Trial / NCT05799716

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

NCT05799716 ↗

Phase 4 Unknown 40 enrolled Shanghai Changzheng Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1. How effective IVIG is in preventing donor-derived infections 2. Does IVIG has potential immunomodulatory effect on transplanted organs

Timeline

Start
2023-04-01
Primary completion
2024-04-01
Completion
2024-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Intravenous immunoglobulins Protein / enzyme biologic 0.5 g/kg Intravenous

Indications

acute transplant rejection bacterial infectious disease